Patents by Inventor Geneviève Renauld-Mongenie

Geneviève Renauld-Mongenie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190117684
    Abstract: The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by Neisseria meningitidis especially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LOS) of N. meningitidis in particular constituted by a lipid A, an inner core, an ? chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain of N. meningitidis that is capable of expressing such an LOS. The invention also relates to a strain of N. meningitidis of serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an ? chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7.
    Type: Application
    Filed: November 1, 2018
    Publication date: April 25, 2019
    Applicant: Sanofi Pasteur SA
    Inventors: Noelle Mistretta, Monique Moreau, Genevieve Renauld-Mongenie, Bachra Rokbi
  • Patent number: 10232029
    Abstract: The invention relates to immunogenic compositions comprising at least two Neisseria meningitidis (Nm) protein antigens selected from the group consisting of a trypsin-like serine protease auto-transporter antigen such as IgAI P, App or AusI antigen, a NalP antigen and a TbpB antigen. Preferably, the composition of the invention comprises (i) the trypsin-like serine protease auto-transporter antigen and (ii) the NalP antigen and/or TbpB antigen.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: March 19, 2019
    Assignee: Sanofi Pasteur
    Inventors: Genevieve Renauld-Mongenie, Bachra Rokbi, Noelle Mistretta
  • Patent number: 10137145
    Abstract: The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by Neisseria meningitidis especially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LOS) of N. meningitidis in particular constituted by a lipid A, an inner core, an ? chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain of N. meningitidis that is capable of expressing such an LOS. The invention also relates to a strain of N. meningitidis of serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an ? chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: November 27, 2018
    Assignee: Sanofi Pasteur SA
    Inventors: Noelle Mistretta, Monique Moreau, Genevieve Renauld-Mongenie, Bachra Rokbi
  • Publication number: 20180125960
    Abstract: The present invention relates to novel polypeptides derived from meningitis proteins, in particular auto-transporters of the subtilinase subclass, and their use in vaccines and vaccine compositions for the prevention and/or treatment of meningitis and meningococcal infections.
    Type: Application
    Filed: December 8, 2015
    Publication date: May 10, 2018
    Inventors: Nadège ARNAUD-BARBE, Geneviève RENAULD-MONGENIE, Bachra ROKBI
  • Publication number: 20180125961
    Abstract: The present invention relates to novel polypeptides derived from Neisseria meningitidis proteins, in particular auto-transporters of the trypsin-like serine protease subclass, such as IgA1P, App and AusI, and their use in immunogenic compositions i.a., vaccine compositions for the prevention and/or treatment of meningococcal infections. In particular, it provides fragments of IgA1P, App and AusI and polypeptides comprising or consisting of these fragments and fusions thereof, which may be used in immunogenic compositions, for example vaccine compositions.
    Type: Application
    Filed: December 8, 2015
    Publication date: May 10, 2018
    Inventors: Nadège ARNAUD-BARBE, Geneviève RENAULD-MONGENIE, Bachra ROKBI
  • Publication number: 20180125959
    Abstract: The invention relates to immunogenic compositions comprising at least two Neisseria meningitidis (Nm) protein antigens selected from the group consisting of a trypsin-like serine protease auto-transporter antigen such as IgAI P, App or AusI antigen, a NalP antigen and a TbpB antigen. Preferably, the composition of the invention comprises (i) the trypsin-like serine protease auto-transporter antigen and (ii) the NalP antigen and/or TbpB antigen.
    Type: Application
    Filed: December 8, 2015
    Publication date: May 10, 2018
    Inventors: Geneviève RENAULD-MONGENIE, Bachra ROKBI, Noëlle MISTRETTA
  • Publication number: 20180036339
    Abstract: The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by Neisseria meningitidis especially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LQS) of N. meningitidis in particular constituted by a lipid A, an inner core, an ? chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain of N. meningitidis that is capable of expressing such an LOS. The invention also relates to a strain of N. meningitidis of serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an ? chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7.
    Type: Application
    Filed: May 2, 2017
    Publication date: February 8, 2018
    Applicant: Sanofi Pasteur SA
    Inventors: Noelle Mistretta, Monique Moreau, Genevieve Renauld-Mongenie, Bachra Rokbi
  • Patent number: 9669052
    Abstract: The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by Neisseria meningitidis especially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LOS) of N. meningitidis in particular constituted by a lipid A, an inner core, an ? chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain of N. meningitidis that is capable of expressing such an LOS. The invention also relates to a strain of N. meningitidis of serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an ? chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: June 6, 2017
    Assignee: Sanofi Pasteur SA
    Inventors: Noelle Mistretta, Monique Moreau, Genevieve Renauld-Mongenie, Bachra Rokbi
  • Publication number: 20160045535
    Abstract: The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by Neisseria meningitidis especially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LOS) of N. meningitidis in particular constituted by a lipid A, an inner core, an ? chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain of N. meningitidis that is capable of expressing such an LOS. The invention also relates to a strain of N. meningitidis of serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an ? chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7.
    Type: Application
    Filed: August 5, 2015
    Publication date: February 18, 2016
    Applicant: Sanofi Pasteur SA
    Inventors: Noelle Mistretta, Monique Moreau, Genevieve Renauld-Mongenie, Bachra Rokbi
  • Patent number: 9132181
    Abstract: The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by Neisseria meningitidis especially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LOS) of N. meningitidis in particular constituted by a lipid A, an inner core, an ? chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain of N. meningitidis that is capable of expressing such an LOS. The invention also relates to a strain of N. meningitidis of serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an ? chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: September 15, 2015
    Assignee: Sanofi Pasteur SA
    Inventors: Noëlle Mistretta, Monique Moreau, Geneviève Renauld-Mongenie, Bachra Rokbi
  • Patent number: 8309100
    Abstract: The invention concerns nucleic acids coding for polypeptides specific of the Neisseria genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: November 13, 2012
    Assignees: Aventis Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Luc Aujame, Annabelle Bouchardon, Geneviève Renauld-Mongenie, Bachra Rokbi, Xavier Nassif, Colin Tinsley, Agnès Perrin
  • Publication number: 20120156281
    Abstract: The invention relates to a vaccine against N. meningitidis infections, comprising (i) an N. meningitidis LOS especially consisting of a lipid A, an inner core, and an L8-type ? chain in which the heptose II residue of the inner core (a) carries a phosphoethanolamine (PEA) substituent in position O-3, and does not carry a PEA substituent in positions O-6 and O-7, or (b) carries a phosphoethanolamine (PEA) substituent in position O-3 and in position O-6 or O-7; and (ii) the lipidated sub-unit B (TbpB) of the receptor of the human transferrine of an N. meningitidis strain or a lipid fragment of said TbpB.
    Type: Application
    Filed: May 12, 2010
    Publication date: June 21, 2012
    Applicant: SANOFI PASTEUR
    Inventors: Jean Haensler, Bruno Guy, Noëlle Mistretta, Monique Moreau, Geneviève Renauld-Mongenie, Bachra Rokbi
  • Publication number: 20100330160
    Abstract: The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by Neisseria meningitidis especially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LOS) of N. meningitidis in particular constituted by a lipid A, an inner core, an ? chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain of N. meningitidis that is capable of expressing such an LOS. The invention also relates to a strain of N. meningitidis of serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an ? chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7.
    Type: Application
    Filed: May 14, 2010
    Publication date: December 30, 2010
    Applicant: Sanofi Pasteur
    Inventors: Noëlle Mistretta, Monique Moreau, Geneviève Renauld-Mongenie, Bachra Rokbi
  • Publication number: 20100184639
    Abstract: The invention concerns nucleic acids coding for polypeptides specific of the Neisseria genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.
    Type: Application
    Filed: February 4, 2010
    Publication date: July 22, 2010
    Inventors: Luc AUJAME, Annabelle Bouchardon, Geneviève Renauld-Mongenie, Bachra Rokbi, Xavier Nassif, Colin Tinsley, Agnes Perrin
  • Patent number: 7704513
    Abstract: The invention concerns nucleic acids coding for polypeptides specific of the Neisseria genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: April 27, 2010
    Assignees: Aventis Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Luc Aujame, Annabelle Bouchardon, Geneviève Renauld-Mongenie, Bachra Rokbi, Xavier Nassif, Colin Tinsley, Agnès Perrin
  • Publication number: 20090155886
    Abstract: The invention concerns nucleic acids coding for polypeptides specific of the Neisseria genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.
    Type: Application
    Filed: March 27, 2008
    Publication date: June 18, 2009
    Inventors: Luc AUJAME, Annabelle Bouchardon, Genevieve Renauld-Mongenie, Bachra Rokbi, Xavier Nassif, Colin Tinsley, Agnes Perrin
  • Patent number: 7384768
    Abstract: The invention concerns nucleic acids coding for polypeptides specific of the Neisseria genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.
    Type: Grant
    Filed: August 3, 2004
    Date of Patent: June 10, 2008
    Assignees: Aventis Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Luc Aujame, Annabelle Bouchardon, Geneviève Renauld-Mongenie, Bachra Rokbi, Xavier Nassif, Colin Tinsley, Agnès Perrin
  • Publication number: 20050032103
    Abstract: The invention concerns nucleic acids coding for polypeptides specific of the Neisseria genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.
    Type: Application
    Filed: August 3, 2004
    Publication date: February 10, 2005
    Inventors: Luc Aujame, Annabelle Bouchardon, Genevieve Renauld-Mongenie, Bachra Rokbi, Xavier Nassif, Colin Tinsley, Agnes Perrin
  • Patent number: 6835384
    Abstract: The invention concerns nucleic acids coding for polypeptides specific of the Neisseria genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.
    Type: Grant
    Filed: August 16, 2001
    Date of Patent: December 28, 2004
    Assignees: Aventis Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Luc Aujame, Annabelle Bouchardon, Geneviève Renauld-Mongenie, Bachra Rokbi, Xavier Nassif, Colin Tinsley, Agnès Perrin